MYR

Antios Therapeutics

This clinical-stage biopharmaceutical company develops antiviral therapies to treat and cure patients with chronic hepatitis B virus infections.

Atea Pharmaceuticals

This biopharmaceutical company develops oral antiviral therapies to treat patients with serious viral infections, including hepatitis C and hepatitis E.

Bluejay Therapeutics

The company develops monoclonal antibody therapies and small molecule drugs to treat patients with chronic hepatitis B, hepatitis D and other liver diseases.

AKRO

This company develops injectable medicines to treat patients with serious metabolic diseases, primarily metabolic dysfunction-associated steatohepatitis.

AusperBio

This biopharmaceutical company develops oligonucleotide therapies and targeted delivery platforms for patients with chronic hepatitis B and other genetic or viral diseases.

Corus Pharmaceuticals

This company develops biopharmaceutical medicines to treat patients with HIV, viral hepatitis, cancer and inflammatory diseases.

Mirum

Mirum Pharmaceuticals develops and commercialises therapies for patients with rare cholestatic liver diseases and other debilitating conditions.

nChroma Bio

The company develops liver-targeted epigenetic editing therapies and non-viral delivery systems to treat patients with chronic hepatitis B and hepatitis D.